Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

Nasal spray offers an alternative for patients ... this is exactly the response required.” As part of the approval process, the FDA asked Belhaven Biopharma to determine if one dose of Nasdepi ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...

Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as "acute repetitive ...

The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine ...